medcelerator · clinician one-pager

First FDA-Approved Treatment for Alexander Disease

Zanvastro (zilganersen) for Alexander disease (AxD)

FDA Approved · United States · September 7, 2026

Condition: Alexander Disease

Who this is for

Zanvastro (zilganersen) is the first approved medicine for Alexander disease, a very rare brain disease. The United States approved it on 3 September 2026. It is injected into the spinal fluid every 3 months.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220210Orig1s000ltr.pdf

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/zanvastro-zilganersen